Nov 20, 2025 4:01pm EST Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Nov 14, 2025 4:01pm EST Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Aug 19, 2025 8:00am EDT Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Aug 14, 2025 4:50pm EDT Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
May 14, 2025 4:05pm EDT Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Apr 14, 2025 8:00am EDT Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Mar 27, 2025 4:01pm EDT Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Feb 18, 2025 8:00am EST Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Nov 14, 2024 8:37am EST Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity